ITGA5 and breast cancer: In triple-negative breast cancer cells with high ITGA5 expression, knockdown of ITGA5 or treatment with miR-30 mimics significantly reduces bone-metastatic burden in vivo, underscoring the pivotal role of ITGA5 in breast cancer bone dissemination (Croset et al., 2018).